Compass Pathways (NASDAQ:CMPS) Raised to “Hold” at Wall Street Zen

Compass Pathways (NASDAQ:CMPS – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday, Wall Street Zen reports.

CMPS has been the subject of a number of other reports. B. Riley Financial boosted their price objective on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Compass Pathways in a report on Wednesday, November 4th. Morgan Stanley raised their target price on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. HC Wainwright reiterated a “buy” rating on shares of Compass Pathways in a report on Monday, November 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Compass Pathways currently has an average rating of “Moderate Buy” and an average target price of $23.14.

Read Our Latest Stock Analysis on Compass Pathways

Compass Pathways Stock Down 3.5%

Shares of CMPS stock opened at $7.98 on Monday. The stock’s 50 day simple moving average is $11.67 and its 200 day simple moving average is $10.47. Compass Pathways has a twelve month low of $4.88 and a twelve month high of $15.87. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.50 and a current ratio of 1.50. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -2.29 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. As a group, research analysts predict that Compass Pathways will post -0.78 EPS for the current year.

Institutional Trading of Compass Pathways

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its holdings in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares during the period. Parallel Advisors LLC grew its position in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares during the last quarter. Ancora Advisors LLC acquired a new stake in Compass Pathways in the 2nd quarter worth $43,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Compass Pathways during the 3rd quarter worth about $85,000. Finally, Entropy Technologies LP bought a new position in shares of Compass Pathways during the 1st quarter worth about $110,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

(Get Free Report)

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.

Featured Articles

Analyst Recommendations for Compass Pathways (NASDAQ:CMPS)

Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.